Wednesday, July 8, 2026

Patent intelligence · US

US 11708410

Antibodies and variants thereof against TIGIT

granted A61KA61K2039/505A61K39/39541A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 26
Patent details — US 11708410
Jurisdiction
US
Status
granted
Grant date
Jul 25, 2023
Expiration
Jul 20, 2043
Claims
23
CPC classes
A61K, A61K2039/505, A61K39/39541, A61K45/06
View on Google Patents ↗

Quick answer

US 11708410 (Antibodies and variants thereof against TIGIT) is held by Nanjing Legend Biotech Co., Ltd. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
23
CPC classes
A61K, A61K2039/505, A61K39/39541, A61K45/06, A61P, A61P31/00

More from Nanjing Legend Biotech Co., Ltd

Related pharmaceutical patents in our USPTO index.

  1. US 12421292

    Anti-DLL3 chimeric antigen receptors and uses thereof

    Legend Biotech Ireland Limited · Expires Sep 18, 2045

    granted
  2. US 12351638

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    LEGEND BIOTECH USA INC. · Expires Jul 3, 2045

    granted
  3. US 12275788

    Single-domain antibodies against CD33 and constructs thereof

    Legend Biotech Ireland Limited · Expires Apr 10, 2045

    granted
  4. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Nanjing Legend Biotech Co., Ltd · Expires Mar 20, 2045

    granted
  5. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    MAB-LEGEND BIOTECH CO., LTD. · Expires Feb 27, 2045

    granted
  6. US 12168688

    Antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Expires Dec 12, 2044

    granted
  7. US 12097219

    Single-domain antibodies against CLL1 and constructs thereof

    Legend Biotech Ireland Limited · Expires Sep 19, 2044

    granted
  8. US 12006363

    Anti-tetraspanin 33 agents and compositions and methods for making and using the same

    BioLegend, Inc. · Expires Jun 6, 2044

    granted

Frequently asked questions

What is US patent 11708410?

US 11708410 (Antibodies and variants thereof against TIGIT) is held by Nanjing Legend Biotech Co., Ltd. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11708410?

Nanjing Legend Biotech Co., Ltd is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 11708410 expire?

Our index shows an expiration date of Jul 20, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.